Media Coverage

Advanced Search
  • 07152021
    Tampa Bay Times

    The coronavirus pandemic has revealed and exacerbated the health and healthcare disparities that have long affected underserved communities. Those who suffer from chronic illnesses may have delayed or stopped testing and treatment during the pandemic. That’s why Quest Diagnostics is teaming up with former Tampa Bay Buccaneer Warrick Dunn and several Tampa Bay nonprofits to provide free health services to those 18 and older.

  • 07152021

    Almost everyone expected 2020 would be a difficult year for substance abuse. On Wednesday, the Centers for Disease Control released the latest drug overdose death statistics showing not only the scope of the addiction crisis but the prevalence of fentanyl in illicit drug fatalities. Dr. Jeff Gudin, a senior medical adviser in drug monitoring and toxicology for Quest Diagnostics, started noticing a worrying trend of polysubstance abuse pick up in the spring of 2020 while monitoring the results of drug tests.

  • 07122021
    Clinical Lab Products

    With the implementation of Pap tests and testing for the human papillomavirus (HPV), cervical cancer rates have significantly declined. However, in recent years, a debate has emerged about the benefit of cotesting, that is Pap plus HPV together, versus HPV primary alone, leaving patients and many clinicians confused about what is the best path to monitor their cervical health; By Damian P. Alagia, III, MD.

  • 07012021
    NBC News

    A study published in May found that screening for STDs in the U.S. dropped by 40 percent from the start of the pandemic in late February 2020 to April 2020. Testing rebounded in June 2020, but by then, positivity rates for chlamydia and gonorrhea had both increased from the year before.

  • 06232021
    Crain's New York Business

    Pfizer, Johnson & Johnson and Quest Diagnostics recently released corporate social responsibility reports detailing their efforts to promote access, diversity and inclusion both internally and externally among the communities they serve. "We continue to have conversations between supervisors and team members on what we need to address," said Cecilia McKenney, senior vice president and chief human resource officer, Quest Diagnostics.

  • 06172021
    Associated Press

    Choose Healthy Life, a national initiative involving Black clergy, United Way of New York City and others, has been awarded a $9.9 million U.S. Department of Health and Human Services grant to expand vaccinations. The federal funding will help establish an infrastructure to start screenings. Quest Diagnostics and its foundation has already provided funding and testing help.

  • 06152021
    Capitol Beat

    With COVID-19 vaccinations lagging in Georgia, a newly formed coalition launched an initiative Tuesday to convince unvaccinated Georgians to get tested for the virus. With vaccine hesitancy remaining high not only in Georgia but across the country, ACT Against COVID is being rolled out nationwide through a partnership with Quest Diagnostics.

  • 06132021
    Waterbury Republican-American

    Rusckowski’s company, a top provider of clinical diagnostic services nationwide, received approval from the U.S. Food and Drug Administration on Feb. 29, 2020 to start creating COVID-19 tests. The first tests Quest supplied came March 10, 2020. More than 15 months later, Quest has supplied about 48 million tests.

  • 06042021
    Contemporary OBGYN

    As screening rates went down for gonorrhea and chlamydia during the COVID-19 pandemic, weekly positivity rates increased, according to Quest Diagnostics’ 2020 Health Trends Study®. The results were published in the American Journal of Preventive Medicine.

  • 05282021
    Georgia Public Broadcasting

    GPB's Ellen Eldridge talks with Dr. Harvey Kaufman about a new study showing rates of HCV testing declined during the pandemic. Health experts are now recommending all adults get tested and, if positive for HCV, start treatment early to prevent serious liver disease and death from hepatitis C.